白蛋白结合型紫杉醇联合替吉奥治疗老年晚期胰腺癌的临床效果

Abstract
Figure/Table
References (19)
Related Citation (15)

Download: PDF (0 KB) HTML (36 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Albumin-bound Paclitaxel combined with Tegafur Gimeracil Oteracil Potassium in the treatment of elderly advanced pancreatic cancer.Methods A total of 50 elderly patients with advanced pancreatic cancer admitted to the Fifth People′s Hospital of Dalian from January 2018 to January 2020 were selected as the research subjects.By the random number table method,they were divided into test group (n=25) and control group (n=25).Patients in the test group were treated with Albumin-bound Paclitaxel combined with Tegafur Gimeracil Oteracil Potassium,and in the control group,Gemcitabine was used.The clinical efficacy,overall survival,median survival and 6-month survival rate of the two groups were compared.The adverse reactions of the two groups were also compared.Results The disease control rate and 6-month survival rate of the test group were higher than those of the control group,the overall survival and median survival were longer than those of the control group,with statistically significant differences (P<0.05).There was no statistical difference in the effectiveness rate between the two groups (P>0.05).The incidence rates of adverse reactions such as leukopenia,thrombocytopenia and nausea and vomiting in the test group were lower than those in the control group,and the differences were statistically significant (P<0.05).Conclusion For elderly patients with advanced pancreatic cancer,the combination of Albumin-bound Paclitaxel and Tegafur Gimeracil Oteracil Potassium has good efficacy and safety for them.

Key words： Advanced pancreatic cancer in the elderly Albumin-bound Paclitaxel Tegafur Gimeracil Oteracil potassium Gemcitabine

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	PAN Ren-feng

Cite this article:

PAN Ren-feng. Clinical effect of Albumin-bound Paclitaxel combined with Tegafur Gimeracil Oteracil Potassium in the treatment of elderly advanced pancreatic cancer[J]. 中国当代医药, 2021, 28(4): 169-172.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I4/169

[1]	Bray F，Ferlay J，Soerjomataram I，et al.Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].C A Cancer J Clin，2018，68（6）：394-424.
[2]	Siegel RL，Miller KD，Jemal A.Cancer statistics，2019[J].C A Cancer J Clin，2019，69（1）：7-34.
[3]	马少军，屈振亮，孔棣，等.胰腺癌流行病学及诊断研究进展[J].中国中西医结合外科杂志，2015，28（1）：87-92.
[4]	Kamarajah SK，Burns WR，Frankel TL，et al.Validation of the American Joint Commission on Cancer （AJCC） 8thedition staging system for patients with pancreatic adenocarcinoma：a Surveillance，Epidemiology and End Results（SEER）analysis[J].Ann Surg Oncol，2017，24（7）：2023-2030.
[5]	李思锐，杨芳，张德慧，等.白蛋白结合型紫杉醇联合替吉奥治疗老年晚期胰腺癌的效果及安全性研究[J].世界复合医学，2019，5（10）：112-114.
[6]	李廷，姜华敏，杨彬.替吉奥单药对比吉西他滨单药一线治疗老年晚期胰腺癌的临床效果分析[J].当代医学，2018，24（13）：114-115.
[7]	李光.白蛋白结合型紫杉醇联合替吉奥治疗老年晚期胰腺癌临床疗效[J].继续医学教育，2019，33（1）：136-138.
[8]	魏蕾，李自雄，秦叔逵，等.吉西他滨单药或联合白蛋白结合型紫杉醇治疗东亚人群晚期胰腺癌临床疗效的荟萃分析[J].临床肿瘤学杂志，2019，24（2）：137-144.
[9]	Valsecchi ME，Diaz-Canton E，De La Vega M，et al.Recent treatment advances and novel therapies in pancreas cancer：a review[J].J Gastrointest Cancer，2014，45（2）：190-201.
[10]	Wickremsinhe E，Bao J，Smith R，et al.Preclinical absorption，distribution，metabolism，and excretion of an oral amide prodrug of gemicitabine designed to deliver prolonged systemic exposure[J].Pharmaceutics，2013，5（2）：261-276.
[11]	朱斌，刘腾，余克富，等.吉西他滨联合白蛋白结合型紫杉醇化疗方案在胰腺癌治疗中的应用研究[J].中国药学杂志，2015，50（15）：1309-1312.
[12]	Yardley DA.nab-Paclitaxel mechanisms of action and delivery[J].J Control Release，2013，170（3）：365-372.
[15]	韩世炜，孙密芬，施伦波.注射用紫杉醇（白蛋白结合型）与替吉奥联合对进展期胰腺癌疗效观察及安全性评价[J].中国中西医结合消化杂志，2016，24（9）：668-671.
[16]	崔啸晨，马志亮，王志茹.吉西他滨为基础的一线联合疗法治疗胰腺癌研究进展[J].中华普通外科学文献，2016，10（2）：158-162.
[18]	韩倩倩，鲁培，秦艳茹，等.白蛋白结合型紫杉醇联合替吉奥治疗老年晚期胰腺癌的效果及安全性观察[J].河南医学研究，2018，27（9）：1561-1563.
[19]	刘甜，熊琦，胡毅.白蛋白结合型紫杉醇联合替吉奥一线治疗老年晚期胰腺癌患者的临床观察[J].现代肿瘤医学，2018，26（5）：722-725.
[13]	Neuzillet C，Tijeras-Raballand A，Cros J，et al.Stromal expression of SPARC in pancreatic adenocarcinoma [J].Cancer Metastasis Rev，2013，32（3-4）：585-602.
[14]	Hoy SM.Albumin-bound paclitaxel：a review of its use for the firstline combination treatment of metastatic pancreatic cancer[J].Drugs，2014，74（15）：1757-1768.
[17]	Imaoka H，Kou T，Tanaka M，et al.Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1，S-1 alone，or gemcitabine alone：Subgroup analysis of a randomised phase Ⅲtrial，GEST study[J].Eur J Cancer，2016，54：96-103.